Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Endocr Pract ; 21(10): 1161-70, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26121440

RESUMEN

OBJECTIVE: To describe the history, refinements, implementation, physiology, and clinical outcomes achieved over the past several centuries of thyroid hormone replacement strategies. METHODS: A Medline search was initiated using the following search terms: bioidentical thyroid hormone, thyroid hormone extract, combination thyroxine (T4) and tri-iodothyronine (T3) therapy, homeopathic thyroid hormone therapy, and thyroid hormone replacement. Pertinent articles of interest were identified by title (and where available abstract) for further review. Additional references were identified during a review of the identified literature. RESULTS: A rich history of physician intervention in thyroid dysfunction was identified dating back more than 2 millennia. Although not precisely documented, thyroid ingestion from animal sources had been used for centuries but was finally scientifically described and documented in Europe over 130 years ago. Since the reports by Bettencourt and Murray, there has been a continuous documentation of outcomes, refinement of hormone preparation production, and updating of recommendations for the most effective and safe use of these hormones for relieving the symptoms of hypothyroidism. As the thyroid extract preparations contain both levothyroxine (LT4) and liothyronine (LT3), current guidelines do not endorse their use as controlled studies do not clearly document enhanced objective outcomes compared with LT4 monotherapy. Among current issues cited, the optimum ratio of LT4 to LT3 has yet to be determined, and the U.S. Food and Drug Administration (FDA) does not appear to be monitoring the thyroid hormone ratios or content in extract preparations on the market. Taken together, these limitations are important detriments to the use of thyroid extract products. CONCLUSION: The evolution of thyroid hormone therapies has been significant over the extended period of time they have been in use to treat hypothyroidism. Although numerous websites continue to advocate the use of thyroid hormone extracts as a superior therapy for hypothyroidism, none of the most recent guidelines of major endocrine societies recommend thyroid extract use for hypothyroidism.


Asunto(s)
Terapia de Reemplazo de Hormonas/historia , Hipotiroidismo/terapia , Glándula Tiroides/química , Extractos de Tejidos/uso terapéutico , Suplementos Dietéticos , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Historia Antigua , Terapia de Reemplazo de Hormonas/métodos , Humanos , Guías de Práctica Clínica como Asunto , Glándula Tiroides/fisiología , Hormonas Tiroideas/fisiología , Hormonas Tiroideas/uso terapéutico , Extractos de Tejidos/farmacocinética
2.
Molecules ; 20(5): 7719-36, 2015 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-25927901

RESUMEN

Radix Inulae is endemic to China and has been used in traditional medicine to treat upper body pain, emesis and diarrhoea, and to eliminate parasites. Here, an UPLC-MS/MS method was developed and applied to study the pharmacokinetics, distribution and excretion of isoalantolactone and alantolactone, which are two main active sesquiterpene lactones in Radix Inulae, in Sprague-Dawley rats following oral administration of total Radix Inulae extract. Isoalantolactone, alantolactone and osthole (internal standard) were prepared using acetonitrile precipitation, and the separation of isoalantolactone and alantolactone was achieved by isocratic elution using water (containing 0.1% formic acid) and acetonitrile as the mobile phase using a ZORBAX Eclipse Plus C18 column. The total run time was 6.4 min. The present study showed poor absorption of isoalantolactone and alantolactone in vivo. The apparent Cmax, Tmax, T1/2 and total exposure (AUC0-12h) in rat plasma were 37.8 ng/mL, 120 min, 351.7 min and 6112.3 ng-min/mL for isoalantolactone and 25.9 ng/mL, 90 min, 321.0 min and 4918.9 ng-min/mL for alantolactone, respectively. It was shown that the highest concentration was achieved in the small intestine and feces clearance was shown to be the dominant elimination pathway of the lactones.


Asunto(s)
Gastrópodos/metabolismo , Lactonas/metabolismo , Lactonas/farmacocinética , Sesquiterpenos de Eudesmano/metabolismo , Sesquiterpenos de Eudesmano/farmacocinética , Sesquiterpenos/metabolismo , Sesquiterpenos/farmacocinética , Administración Oral , Animales , Cromatografía Liquida , Masculino , Medicina Tradicional China , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem , Extractos de Tejidos/administración & dosificación , Extractos de Tejidos/metabolismo , Extractos de Tejidos/farmacocinética
3.
Biosci Biotechnol Biochem ; 62(7): 1307-12, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9720212

RESUMEN

The effects of a total bone extract (TBE), a new mineral preparation made from bovine bone rendered soluble by lactic acid and citric acid under decompression, on the bone metabolism and apparent calcium absorption were examined for an ovariectomized (OVX) rat model of osteoporosis. The apparent calcium absorption from TBE was significantly higher than that from calcium carbonate. There were no significant differences in serum biochemical indices. Although there were no significant differences in the dry weight, ash and calcium content in the tibia, or in the bone mineral density of the femur, TBE feeding increased the cortical thickness index of the femur. A positive effect of TBE on bone formation is thus suggested.


Asunto(s)
Densidad Ósea/efectos de los fármacos , Calcio/farmacocinética , Fémur/efectos de los fármacos , Extractos de Tejidos/farmacología , Animales , Disponibilidad Biológica , Biomarcadores/sangre , Calcio/sangre , Carbonato de Calcio/farmacocinética , Ácido Cítrico , Femenino , Fémur/metabolismo , Humanos , Absorción Intestinal/efectos de los fármacos , Ácido Láctico , Magnesio/sangre , Masculino , Osteoporosis Posmenopáusica/sangre , Osteoporosis Posmenopáusica/tratamiento farmacológico , Ovariectomía , Fósforo/sangre , Ratas , Ratas Endogámicas F344 , Ratas Sprague-Dawley , Extractos de Tejidos/farmacocinética
4.
Pharmazie ; 51(8): 577-81, 1996 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-8975251

RESUMEN

With a specific radioimmunoassay the pharmacokinetics and relative bioavailability of escin was measured after administration of different formulations containing Aesculus-extract. Of special interest was the relative bioavailability of escin after administration of a newly developed film-coated tablet with sustained release in comparison to a reference formulation. In a cross-over steady-state study in 24 volunteers bioequivalence of test and reference preparation could be demonstrated. The 90% confidence interval of the AUC (O-tau) was 98.3 to 120.9%.


Asunto(s)
Escina/farmacocinética , Plantas Medicinales/química , Adulto , Disponibilidad Biológica , Estudios Cruzados , Escina/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Radioinmunoensayo , Comprimidos Recubiertos , Equivalencia Terapéutica , Extractos de Tejidos/farmacocinética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA